Agenus Inc (STU:AJ8)
€ 7.952 0 (0%) Market Cap: 159.15 Mil Enterprise Value: 160.92 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 46/100

Agenus Inc Corporate Analyst Meeting Transcript

Feb 20, 2020 / 02:00PM GMT
Release Date Price: €67.02 (-0.61%)
Garo H. Armen
Agenus Inc. - Founder, Executive Chairman & CEO

It's 2 minutes past the hour, so we will start as promptly as possible. Firstly, thank you very much for being here today. We appreciate your time. I know for investors, this is a precious time as the market will be opening soon. So we particularly appreciate your efforts to be here.

Let me start by -- I guess I'm controlling things here -- with our disclosure of forward-looking statements. All I'll say is that there's a lot more detail on our website on this and in our SEC filings, so we invite you to do that.

We have -- over the years, as you know, we have been in the cancer immunotherapy business for -- it'll be 26 years in April. The company was formed 26 years ago. And so it's been a long haul. And it's been a long haul with no regrets because the field of cancer immunotherapy has advanced to the point where now it is the most promising treatment modality for cancer patients going forward. Of course, I'm not suggesting that nothing else will be used, but cancer immunotherapy is front and center, stating the obvious,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot